Biosocieties

Papers
(The TQCC of Biosocieties is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Facing the unknown suspect: forensic DNA phenotyping and the oscillation between the individual and the collective23
Rethinking value construction in biomedicine and healthcare15
Doing the individual and the collective in forensic genetics: governance, race and restitution11
The coughing body: etiquettes, techniques, sonographies and spaces9
Life’s continuation: repro-tech, biogenetic affinity, and racial capitalism9
Core values of genomic citizen science: results from a qualitative interview study8
Imagining the public: anticipatory discourses in China’s push for precision medicine7
Reprowebs: a conceptual approach to elasticity and change in the global assisted reproduction industry6
Mutual visibility and interaction: staff reactions to the ‘healing architecture’ of psychiatric inpatient wards in Denmark5
Vegetative value: promissory horizons of therapeutic innovation in the global circulation of ayahuasca5
Powering life through MitoTechnologies: exploring the bio-objectification of mitochondria in reproduction5
The Covid-19 caesura and the post-pandemic future5
To wish you well: the biopolitical subjectivities of medical crowdfunders during and after Aotearoa New Zealand’s COVID-19 lockdown5
The emergence of multimorbidity as a matter of concern: a critical review5
Value-creation in the health data domain: a typology of what health data help us do4
The datafication of pain: trials and tribulations in measuring phantom limb pain4
Beyond secrecy and openness: telling a relational story about children’s best interests in donor-conceived families4
Psychedelic innovations and the crisis of psychopharmacology4
Beyond the making of altruism: branding and identity in egg donation websites in Spain4
‘The good economy’: a conceptual and empirical move for investigating how economies and versions of the good are entangled4
The antidepressant in women’s lifeworlds: feminist materialist encounters4
Legitimate suffering: a case of belonging and sickle cell trait in Brazil3
Making valuable health: pharmaceuticals, global capital and alternative political economies3
Device activism and material participation in healthcare: retracing forms of engagement in the #WeAreNotWaiting movement for open-source closed-loop systems in type 1 diabetes self-care3
“It’s harder for the likes of us”: racially minoritised stem cell donation as ethico-racial imperative3
“Asperger’s syndrome does not exist”: the limits of brain-based identity discourses around Asperger’s syndrome and autism in Italy3
Pharmaceutical innovation and its crisis: drug markets, screening, and the dialectics of value3
Acting on uncertainty: real-life mixtures of endocrine disrupting chemicals3
N = many me’s: self-surveillance for Precision Public Health3
Making epistemic goods compatible: knowledge-making practices in a lifestyle intervention RCT on mindfulness and compassion meditation3
Fake eggs: from counter-qualification to popular certification in China’s food safety crisis3
The FDA’s standard-making process for medical digital health technologies: co-producing technological and organizational innovation3
Concussion killjoys: CTE, violence and the brain’s becoming3
The life and death of confidentiality: a historical analysis of the flows of patient information3
Value regimes and pricing in the pharmaceutical industry: financial capital inflation (hepatitis C) versus innovation and production capital savings for malaria medicines3
0.074026107788086